Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel
3 Biotech, 2026;16(8):312
From Weight Loss to Organ-Specific Disease Modification: A Narrative Review of Incretin-Based Therapies in Obesity-Related Cardiometabolic Disease, Chronic Kidney Disease, Metabolic Dysfunction-Associated Steatohepatitis, and Obstructive Sleep Apnoea
Cureus, 2026;18(7):e112135
Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers
Alimentary pharmacology & therapeutics, 2026
Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets
Pharmaceutics, 2026;18(7)
Quantitative MRI Pharmacokinetic Modeling and MALDI Mass Spectrometry Imaging Biodistribution of a pH Mapping MRI Contrast Agent
Theranostics, 2026;16(14):7937-7957
Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study
BMC pulmonary medicine, 2026
GLP-1 receptor agonists in pediatric obesity
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2026
GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles
Pharmacological research, 2026;:108333
Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis
Journal of cardiac failure, 2026
Lead-guided prodrug development of small molecules as GLP-1R agonists
Bioorganic chemistry, 2026;180:110210
Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study
Hepatology international, 2026
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
Cardiovascular drugs and therapy, 2026
Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
The Journal of hand surgery, 2026
Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations
Expert review of endocrinology & metabolism, 2026;:1-9
Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026
PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction
Nature communications, 2026;17(1)
Wernicke’s Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence
Obesity (Silver Spring, Md.), 2026
GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing
Translational research : the journal of laboratory and clinical medicine, 2026
Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology
Journal of the American Academy of Dermatology, 2026
Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study
Therapeutic advances in endocrinology and metabolism, 2026;17:20420188261460592